Catalyst
Slingshot members are tracking this event:
Phase 3 data of Selumetinib SELECT-1 trial for differentiated thyroid cancer, KRAS-mutant non-small cell lung cancer and neurofibromatosis type 1 due 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ARRY | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 09, 2016
Occurred Source:
https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-provides-update-on-Phase-III-trial-of-Selumetinib-in-non-small-cell-lung-cancer-09082016.html
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Kras-mutant Non-small Cell Lung Cancer, Neurofibromatosis Type 1, Differentiated Thyroid Cancer, Phase 3 Data, Selumetinib, Select-1
